← Browse by Condition
Medical Condition
immunotherapy
Total Trials
14
Recruiting Now
14
Trial Phases
Phase 1, Phase 2, Phase 3
NCT07260591 Phase 1
Recruiting
VSV-02 Compassionate Use in Advanced Solid Tumors
Enrollment
6 pts
Location
China
Sponsor
The First Affiliated Hospital ...
NCT06764680 Phase 2
Recruiting
Oral Chemotherapy, Targeted Therapy and Immunotherapy With/Without Radiotherapy as 3rd- or Later-line Therapy for Advanced MSS/pMMR Colorectal Cancer
Enrollment
57 pts
Location
China
Sponsor
Sun Yat-sen University
NCT05967910
Recruiting
The Effect of Chronic Stress on Efficacy of ICIs in Esophageal Cancer Patients (STRESS-ESCA Study)
Enrollment
200 pts
Location
China
Sponsor
Second Xiangya Hospital of Cen...
NCT06676722 Phase 2
Recruiting
SBRT Combined With Nimotuzumab and Tislelizumab for Oligoprogressive Recurrent/Metastatic Nasopharyngeal Carcinoma After Failure of Immunotherapy
Enrollment
20 pts
Location
China
Sponsor
The First Affiliated Hospital ...
NCT06276088
Recruiting
Plasma and Tissue SAA1 Levels in Cancer Patients to Predict Hyperprogression of Immunotherapy
Enrollment
374 pts
Location
China
Sponsor
Nanfang Hospital, Southern Med...
NCT06500234 Phase 3
Recruiting
Nutrition Impact on Immunotherapy of Cancer
Enrollment
300 pts
Location
China
Sponsor
Qingdao Central Hospital
NCT07327489
Recruiting
Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies
Enrollment
2,000 pts
Location
United States
Sponsor
Elephas
NCT06356584 Phase 2
Recruiting
Fruquintinib Combined With Sintilimab ± Radiotherapy for Third-line Treatment of Colorectal Cancer With Liver Metastases
Enrollment
62 pts
Location
China
Sponsor
Shandong Cancer Hospital and I...
NCT06702826 Phase 2
Recruiting
Cadonilimab Combined With Stereotactic Radiotherapy as Second-line Treatment for Brain Metastases
Enrollment
20 pts
Location
China
Sponsor
Rongrong Zhou
NCT05613478 Phase 3
Recruiting
Camrelizumab Combined With Apatinib Mesylate and TACE in the Perioperative Treatment of Hepatocellular Carcinoma
Enrollment
130 pts
Location
China
Sponsor
The First Affiliated Hospital ...
NCT06391190 Phase 1, Phase 2
Recruiting
Concurrent Chemoradiotherapy Followed by PD-1 Inhibitor in Advanced Cervical Cancer
Enrollment
20 pts
Location
China
Sponsor
RenJi Hospital
NCT06738160 Phase 2
Recruiting
The Efficacy and Safety of Narlumosbart in Combination With Stereotactic Body Radiation Therapy to Improve the Efficacy of First-line Chemotherapy Combined With Immunotherapy in Patients With Bone Metastases From Advanced Non-small Cell Lung Cancer
Enrollment
27 pts
Location
China
Sponsor
Fudan University
NCT06608160
Recruiting
68Ga-grazytracer PET Assists in Diagnosing Pseudoprogression Following Immunotherapy in Lung Cancer.
Enrollment
30 pts
Location
China
Sponsor
Ruijin Hospital
NCT06307249 Phase 1
Recruiting
Precision Therapy for Solid Tumors: Synergistic CDK4/6 Inhibition and Anti-VEGF Targeting LncRNA
Enrollment
50 pts
Location
Lebanon
Sponsor
Lebanese University